184 related articles for article (PubMed ID: 36835351)
1. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
Miyachi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835351
[TBL] [Abstract][Full Text] [Related]
2. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
4. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
Miyachi H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
[TBL] [Abstract][Full Text] [Related]
5. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
Ohashi M; Oyama T; Putranto EW; Waku T; Nobusada H; Kataoka K; Matsuno K; Yashiro M; Morikawa K; Huh NH; Miyachi H
Bioorg Med Chem; 2013 Apr; 21(8):2319-2332. PubMed ID: 23490155
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
9. [Design and Synthesis of Peroxisome Proliferator-activated Receptor (PPAR) Gamma Antagonists Based on the Principle of Operation of Nuclear Receptor I].
Ohashi M; Miyachi H
Yakugaku Zasshi; 2017; 137(8):957-967. PubMed ID: 28768949
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARγ).
Ma JJ; Zhang T; Fang N; Zou Y; Gong QH; Yu LM; Chen DX
J Pharm Pharmacol; 2012 May; 64(5):719-26. PubMed ID: 22471368
[TBL] [Abstract][Full Text] [Related]
12. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
[TBL] [Abstract][Full Text] [Related]
13. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis.
Ohashi M; Gamo K; Tanaka Y; Waki M; Beniyama Y; Matsuno K; Wada J; Tenta M; Eguchi J; Makishima M; Matsuura N; Oyama T; Miyachi H
Eur J Med Chem; 2015 Jan; 90():53-67. PubMed ID: 25461311
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists.
Tanaka Y; Gamo K; Oyama T; Ohashi M; Waki M; Matsuno K; Matsuura N; Tokiwa H; Miyachi H
Bioorg Med Chem Lett; 2014 Aug; 24(16):4001-5. PubMed ID: 25017035
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
16. Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPARγ).
Wang J; Wang B; Zhang Y
J Biomol Struct Dyn; 2020 Feb; 38(2):398-409. PubMed ID: 31025599
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
[TBL] [Abstract][Full Text] [Related]
18. Arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists covalently bind to the PPARγ ligand binding domain with a unique binding mode.
Yoshizawa M; Aoyama T; Itoh T; Miyachi H
Bioorg Med Chem Lett; 2022 May; 64():128676. PubMed ID: 35301139
[TBL] [Abstract][Full Text] [Related]
19. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
20. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
